| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2015.08.005 |
| P698 | PubMed publication ID | 26271828 |
| P50 | author | Jorge E. Osorio | Q28743695 |
| Brock Kingstad-Bakke | Q64866566 | ||
| P2093 | author name string | Attapon Kamlangdee | |
| P2860 | cites work | Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization | Q24538818 |
| Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding | Q24676721 | ||
| Effects of route and coadministration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice | Q84868738 | ||
| A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations | Q28749671 | ||
| The structure and function of the hemagglutinin membrane glycoprotein of influenza virus | Q29618354 | ||
| Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene | Q30207890 | ||
| The economic impact of pandemic influenza in the United States: priorities for intervention. | Q30323010 | ||
| Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. | Q30382650 | ||
| Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice | Q30418452 | ||
| Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine | Q30425439 | ||
| Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity | Q33648987 | ||
| Influenza virus neuraminidase: structure, antibodies, and inhibitors | Q34318113 | ||
| Neuraminidase inhibitors for influenza | Q34455162 | ||
| Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. | Q34621661 | ||
| Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection | Q35193034 | ||
| Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium | Q37596932 | ||
| Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins | Q37678602 | ||
| Differences in substrate specificity of myxovirus neuraminidases | Q38362962 | ||
| Immunity to influenza in man | Q40162453 | ||
| Roles of neuraminidase in the initial stage of influenza virus infection | Q40282494 | ||
| Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice | Q40297409 | ||
| Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine | Q40958430 | ||
| Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants | Q41343237 | ||
| Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. | Q41378999 | ||
| Consumption of baits containing raccoon pox-based plague vaccines protects black-tailed prairie dogs (Cynomys ludovicianus). | Q41435324 | ||
| Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition | Q44470799 | ||
| Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection | Q44631148 | ||
| Efficacy of avian influenza neuraminidase-specific vaccines in chickens. | Q44718227 | ||
| Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein | Q44770568 | ||
| Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans | Q44817736 | ||
| Protection of mice with recombinant influenza virus neuraminidase | Q45072351 | ||
| Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice | Q45422701 | ||
| Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation | Q45456530 | ||
| Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs | Q45750930 | ||
| Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein | Q45832694 | ||
| Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes | Q45843904 | ||
| Raccoon poxvirus as a mucosal vaccine vector for domestic cats | Q47326782 | ||
| Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response | Q47773636 | ||
| Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase | Q49093623 | ||
| Recombinant neuraminidase vaccine protects against lethal influenza | Q49167194 | ||
| Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. | Q54606904 | ||
| Economic and social impact of epidemic and pandemic influenza | Q57114320 | ||
| Characterization of Recombinant Raccoonpox Vaccine Vectors in Chickens | Q59850772 | ||
| Protection against lethal influenza with neuraminidase | Q69025488 | ||
| Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: Results of mouse protection experiments | Q71081336 | ||
| Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza | Q77122492 | ||
| P433 | issue | 39 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Raccoonpox virus | Q18964870 |
| P304 | page(s) | 5155-5162 | |
| P577 | publication date | 2015-08-10 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge | |
| P478 | volume | 33 |
| Q30386823 | Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies |
| Q37093491 | Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses |
| Q57094018 | Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness |
| Q40545022 | The genomes of three North American orthopoxviruses |
| Q41933365 | Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. |
| Q30390938 | Viral vector-based influenza vaccines |
| Q63884731 | Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus) |
Search more.